Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04599478 · ClinicalTrials.gov registry record · Phase 2
Pharmacological and Behavioral Treatment After Bariatric Surgery: Acute (Stage 1)
A Phase 2 study of Obesity & Overweight and Loss-of-control Eating, sponsored by Yale University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
- 1
- Study location
NCT04599478: Recruiting Phase 2 study of Obesity & Overweight and Loss-of-control Eating, sponsored by Yale University.
NCT04599478 is a Phase 2 study of Obesity & Overweight and Loss-of-control Eating that is actively recruiting participants, run by Yale University. The registered enrollment target is 160 participants, above the 109-participant average among 28 other Obesity & Overweight trials with a reported enrollment target (47% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04599478, a Phase 2 study of Obesity & Overweight and Loss-of-control Eating, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will compare the effectiveness of behavioral and pharmacologic treatments, alone and in combination, for the treatment of loss-of-control eating and weight following bariatric surgery. This is an acute treatment comparing behavioral weight loss alone or in combination with combination naltrexone/bupropion medication.
Primary Outcome
Loss-of-control eating frequency is a continuous variable of loss-of-control eating episodes assessed using the Eating Disorder Examination interview; Loss-of-control eating frequency will be based on the past 28 days and defined as loss-of-control eating episodes per month.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Naltrexone and Bupropion medication
- BEHAVIORAL Behavioral Weight Loss
Study Locations (1)
Connecticut
- Yale Department of Psychiatry - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2021-06-29 |
| Est. Completion | 2027-01 |
| Phase | Phase 2 |
What NCT04599478 shows while recruiting
NCT04599478 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, above the 109-participant average among 28 other Obesity & Overweight trials with a reported enrollment target (47% higher).
The record links to 2 conditions, with Obesity & Overweight appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT04599478 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT04599478 about?
NCT04599478 is a clinical study titled "Pharmacological and Behavioral Treatment After Bariatric Surgery: Acute (Stage 1)". This study will compare the effectiveness of behavioral and pharmacologic treatments, alone and in combination, for the treatment of loss-of-control eating and weight following bariatric surgery. This is an acute treatment comparing behavioral weight loss alone or in combination with combination nal...
What is the current status of trial NCT04599478?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2021-06-29. Estimated completion is 2027-01.
What conditions does trial NCT04599478 study?
This clinical trial studies the following conditions: Obesity & Overweight, Loss-of-control Eating.
What interventions are being tested in trial NCT04599478?
The interventions under investigation include: Placebo (OTHER), Naltrexone and Bupropion medication (DRUG), Behavioral Weight Loss (BEHAVIORAL).
Who is sponsoring clinical trial NCT04599478?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04599478 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity & Overweight
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04599478's enrollment target sits among peer trials
160 6th of 28 higher than 23 of 28 other Obesity & Overweight trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity & Overweight trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pharmacological and Behavioral Treatments After Bariatric Surgery: Maintenance Treatment (Stage 2a)
ACTIVE NOT RECRUITING · Phase 2
-
Pharmacological and Behavioral Treatment After Bariatric Surgery: Medication Change for Non-Responders (Stage 2b)
ACTIVE NOT RECRUITING · Phase 2
-
Weight Regain Treatment Post-Bariatric Surgery
COMPLETED · Phase 2
-
Optimizing Self-Monitoring Feedback Delivery for the Treatment of Overweight and Obesity
RECRUITING · NA
-
Microrandomized Trial to Optimize Use of Burden-reducing Self-monitoring Approaches in Behavioral Obesity Treatment
RECRUITING · NA
-
Pistachio Intake and Nutrition-Related Outcomes in Individuals on GLP-1 Therapy
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI